Laddar...
Towards personalized treatment for early stage HER2-positive breast cancer
Advances in HER2-targeted therapies have improved the survival of patients with HER2-positive breast cancer. The standard-of-care treatment for localized disease has been chemotherapy and 1 year of adjuvant HER2-targeted therapy, typically with the anti-HER2 antibody trastuzumab. Despite the effecti...
Sparad:
| I publikationen: | Nat Rev Clin Oncol |
|---|---|
| Huvudupphovsmän: | , , , , , , |
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
2019
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8023395/ https://ncbi.nlm.nih.gov/pubmed/31836877 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41571-019-0299-9 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|